Originally published on Best Stocks Category: best stocks to buy now Corp. Amgen (NASDAQ: AMGN) Zacks Research research analysts updated their expectations for Amgen’s FY2024 earnings downward in a study published on November 16. According to K. Shah of Zacks Research, the medical research organization will now report earnings per share of $18.30 for the year, down from their initial projection of $19.63. Amgen’s full-year earnings are presently projected to be valued at $17.64 per share.Other equity research analysts have also lately published their views on AMGN. Robert W. Baird published a research note on shares of Amgen on Tuesday, September 13, with a “underperform” rating reaffirmation and a $185.00 price target. In a research report released on Friday, November 4, Royal Bank of Canada increased their price target on shares of Amgen from $235.00 to $240.00 while maintaining their “sector perform” rating on the stock. TheStreet upgraded the stock of Amgen from a “c+” rating to a “b” on August 15. On Tuesday, August 9, Atlantic Securities maintained an “underweight” rating while lowering their price objective from $190.00 to $182.00 for shares of Amgen. StockNews.com started covering shares of Amgen in a research report on Wednesday, October 12. They suggested that customers “purchase” the company. Six financial experts advise holding the stock, six advise purchasing it, and four advise selling it. According to Bloomberg.com, Amgen now has an average rating of “Hold” and an average target price of $248.19.Amgen’s stock began trading on Monday at $287.29. Amgen’s peak and low prices over the last year have been $296.67 and $198.64, respectively. The company is highly capitalized, with a market value of $153.29 billion, a price-to-earnings ratio of 23.04, a price-to-earnings-growth ratio of 2.30, and a beta of 0.64. The company’s debt-to-equity ratio is 10.17, its current ratio is 1.68, and its quick ratio is 1.35. The fifty-day moving average price of the stock is $252.03, and the 200-day moving average price is $247.72.The most recent earnings report from Amgen (NASDAQ: AMGN) was made public on November 3. The medical research company posted $4.70 EPS for the quarter, $0.26 over analysts’ forecasts. Amgen had a net margin of 25.96% and a return on equity of 287.23%. The company’s sales for the quarter came to $6.65 billion, exceeding the $6.56 billion average projection. During the same period last year, the company’s EPS was $4.67. However, the company’s sales for the quarter decreased by 8.3% compared to the same quarter last year.The business also disclosed a quarterly dividend that would be paid on December 8. In addition, a $1.94 dividend will be paid to shareholders whose shares were of record on November 17. This generates a quarterly return of 2.70% and an annual dividend of $7.76. On Wednesday, November 16, the dividend is due. Amgen’s dividend payout ratio (DPR) is 62.23%.Additionally, SVP Nancy A. Grygiel sold 545 Amgen stock on November 8. The shares were put up for sale for a total asking price of $159,979.30, or an average price of $293.54 per share. Following the completion of the transaction, the Senior Vice President will directly own 13,009 shares of the company’s stock, valued at approximately $3,818,661.86. A document detailing the transaction was submitted to the Securities and Exchange Commission and is available at this URL. Insiders of the business own 0.46% of the shares.